Table 3.
Anti-topoisomerase I antibody-positive versus antibody-negative patients in systemic sclerosis cohort assessed by line immunoblot assay
| Disease manifestation | Patients with disease manifestation | Anti-topoisomerase I | P value | Sensitivity (%) | Specificity (%) | |
| Positive (n = 67) | Negative (n = 213) | |||||
| Digital ulcers | 112 (40.0%) | 38 (56.7%) | 74 (34.7%) | 0.002 | 33.9 | 82.7 |
| Lung fibrosis | 98 (35.0%) | 46 (68.6%) | 52 (24.4%) | <0.0005 | 46.9 | 88.5 |
| DLCO by a single breath | 62.9 ± 20.8 | 72.9 ± 19.9 | <0.0005 | NA | NA | |
| Mean FVC | 81.1 ± 18.0 | 91.8 ± 18.7 | <0.0005 | NA | NA | |
| Pulmonary arterial hypertension | 60 (21.4%) | 17 (25.4%) | 43 (20.2%) | 0.39 | 28.3 | 77.3 |
| Contractures | 162 (57.9%) | 59 (88.1%) | 113 (53.1%) | <0.0005 | 34.3 | 92.6 |
| Renal involvement | 56 (20.0%) | 13 (19.4%) | 43 (20.2%) | 1 | 23.2 | 75.9 |
| Renal crisis | 16 (5.7%) | 6 (9%) | 10 (4.7%) | 0.23 | 37.5 | 76.8 |
| Cardiac involvement | 114 (40.7%) | 33 (49.2%) | 81 (38.0%) | 0.12 | 28.9 | 79.5 |
| Conduction blocks | 69 (24.6%) | 25 (37.3%) | 44 (20.7%) | 0.009 | 36.2 | 80.1 |
| Electrocardiogram changes | 74 (26.4%) | 27 (40.3%) | 47 (22.1%) | 0.007 | 36.5 | 80.4 |
| mRSS | 14.2 ± 10.2 | 5.57 ± 5.8 | <0.0005 | NA | NA | |
| Raynaud's phenomenon | 272 (97.1%) | 67 (100%) | 205 (96.2%) | 0.2 | 24.6 | 100 |
| Diffuse systemic sclerosis | 96 (34.3%) | 58 (86.6%) | 38 (17.8%) | <0.0005 | 60.4 | 95.1 |
| Mean disease activity | 2.49 | 1.63 | <0.0005 | NA | NA | |
Data presented as n (%) or mean ± standard deviation. DLCO, predicted diffusion capacity; FVC, predicted forced vital capacity; mRSS, modified Rodnan skin score; NA, not applicable.